A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Dnth103 In Adults With Chronic Inflammatory Demyelinating Polyneuropathy (Captivate)
Posted Date: Sep 10, 2025
- Investigator: Hani Kushlaf
- Specialties: Neurology, Neuromuscular Disorders
- Type of Study: Drug
Study DNTH103-CIDP-301 is a global, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of DNTH103 in adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
Criteria:
Adult Males And Females = 18-75 Years Of Age (Inclusive) At Screening. Weight Range Between 40 Kg And 120 Kg At Screening. A Diagnosis Of Cidp Or Possible Cidp Per The 2021 European Academy Of Neurology (Ean)/Peripheral Nerve Society (Pns) Guidelines. Must Be Neurologically Stable (Ie, No Relapses Or Other Neurological Events That Could Affect Examinations) At Screening
Keywords:
Cidp
For More Information:
Sara Reiber
5135582968
searss2@ucmail.uc.edu